Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameCirc
Stock Code01763
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities主要從事診斷及治療用放射性藥品及醫用和工業用放射源產品的研究、開發、製造及銷售,並提供輻照滅菌服務及伽瑪射線輻照裝置的設計、製造及安裝的EPC服務,以及向醫院及其他醫療機構提供獨立醫學檢驗實驗室服務。
Listing Date2018-07-06
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京市西城區復興門外大街A2號6層611室
Business Address (Hong Kong)皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitechina-isotope.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 21.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2018-06-22 to 2018-06-27
Global Offering Shares79,968,700 shares
HK Public Offer Shares (Initial)7,997,200 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)71,971,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO319,874,800 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share48.7%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,727,323,920

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.34B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +600%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,741,000,000
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利约人民币475.6百万元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201520162017
Profit for the year 410,382434,502475,638
Balance Sheet
Item 201520162017
Cash and cash equivalents 711,0891,003,2171,478,833
Trade and bills receivables 1,064,7481,214,8571,507,234
Inventories 188,038225,734263,002
Total current assets 2,108,3362,574,7883,459,942
Total current liabilities 1,404,2681,952,5131,916,239
Total equity 1,353,6501,473,4582,446,334
Equity attributable to owners 847,660927,5221,868,944
Interest-bearing borrowings 60,000110,183480,000
Cash Flow Statement
Item 201520162017
Net cash from operating activities 389,536457,633429,760
Net cash from investing activities -76,032-150,378-437,472
Net cash from financing activities -470,988-40,898228,367
Net increase in cash -157,484266,357220,655
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 20.1
First Day OpenHK$ 20.0
First Day Change-6.94%
First Day Volume29619000.0
First Day Turnover599830000.0
Use of Proceeds
1、約41.7%所得款項凈額或約671.17百萬港元預期用于投資分別位于河北省香河及四川省成都市的兩個顯像診斷及治療用放射性藥品生產及研發基地,以提升我們的生產及研發能力; 2、約4.7%所得款項凈額或約75.65百萬港元預期用于建立四間生產及分銷附屬公司,以主要于中國生產及分銷锝[99mTc]標記注射液及氟[18F]脫氧葡糖注射液; 3、約5.9%所得款項凈額或約94.96百萬港元預期用于在廣東省深圳市及安徽省桐城市建立新生產設施,以擴充尿素呼氣試驗藥盒及測試儀的產能; 4、約17.7%所得款項凈額或約284.88百萬港元預期用于投資研發多種顯像診斷及治療用放射性藥品、放射源產品的原材料、醫用放射性同位素及尿素呼氣試驗產品及相關原材料; 5、約20.0%所得款項凈額或約321.90百萬港元預期用于選擇性收購; 6、約10.0%所得款項凈額或約160.95百萬港元預期用作營運資金及一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (2)
中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893
Joint Bookrunners (3)
中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893 农银国际融资有限公司 CE AWL249
Joint Lead Managers (4)
中国国际金融香港证券有限公司 CE AEN894 中信里昂证券有限公司 CE AAB893 农银国际证券有限公司 CE ACX411 中信建投(国际)融资有限公司 CE BAU112

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 北京工业发展投资管理有限公司 235,418,400 HKD — 13.63% — 6 months 2019-01-06
2 上海医药(香港)投资有限公司 172,929,600 HKD — 10.01% — 6 months 2019-01-06
3 通程控股有限公司 257,178,240 HKD — 14.89% — 6 months 2019-01-06
4 中国国有企业结构调整基金股份有限公司 176,148,000 HKD — 10.20% — 6 months 2019-01-06

Directors & Management

PositionChinese nameEnglish Name
Chairman孟琰彬—
Company Secretary吳來水、甘美霞—
No director data available.

Major Shareholders

Major Shareholders & Holdings中核集團直接及間接透過原子能院、核動力院、中核基金、四〇四公司及寶原投資持有本公司全球發售後已發行股本總額約73.83%(假設超額配股權未獲行使),為控股股東。
About this page

This page shows Circ (01763) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect